{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:37:52Z","timestamp":1793144272444,"version":"4.5.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Progressive pulmonary fibrosis is generally diagnosed when interstitial lung disease progression occurs in the absence of any other cause, and a subset of patients with myositis and associated interstitial lung disease may develop progressive pulmonary fibrosis. Numerous autoantibodies (e.g., against tRNA-synthetase, MDA5, Ro52) increase the risk of this clinical feature in myositis and we speculate that serum biomarkers, sought using the most sensitive laboratory techniques available (i.e., immunoprecipitation) may predict pulmonary involvement and allow the early identification of progressive pulmonary fibrosis. We herein provide a narrative review of the literature and also present original data on pulmonary fibrosis in a cohort of patients with myositis and serum anti-Ro52 with interstitial lung disease. Our results fit into the previous evidence and support the association between anti-Ro52 and signs of pulmonary fibrosis in patients with inflammatory myositis. We believe that the combination of available and real-life data has significant clinical relevance as a paradigm of serum autoantibodies that prove useful in determining precision medicine in rare connective tissue diseases.<\/jats:p>","DOI":"10.3389\/fmed.2023.1068402","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T06:44:45Z","timestamp":1678949085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Interstitial lung disease associated with inflammatory myositis: Autoantibodies, clinical phenotypes, and progressive fibrosis"],"prefix":"10.3389","volume":"10","author":[{"given":"Angela","family":"Ceribelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Tonutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Isailovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.semarthrit.2020.09.020","article-title":"Antisynthetase syndrome \u2013 much more than just a myopathy","volume":"51","author":"Opinc","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","article-title":"Inclusion body myositis: clinical features and pathogenesis","volume":"15","author":"Greenberg","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a New classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","article-title":"Classification of myositis","volume":"14","author":"Lundberg","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1093\/rheumatology\/keaa739","article-title":"Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis","volume":"60","author":"Fornaro","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/imj.14789","article-title":"Anti-MDA5-associated dermatomyositis","volume":"50","author":"Gupta","year":"2020","journal-title":"Intern Med J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e751181","DOI":"10.3389\/fmed.2021.751181","article-title":"Variability in global prevalence of interstitial lung disease","volume":"8","author":"Kaul","year":"2021","journal-title":"Front Med [Internet]"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.semarthrit.2020.11.009","article-title":"Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020","volume":"51","author":"Sun","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/BOR.0000000000000663","article-title":"Pulmonary involvement in antisynthetase syndrome","volume":"31","author":"Gasparotto","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","article-title":"Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease","volume":"194","author":"Johnson","year":"2016","journal-title":"Lung"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ccm.2019.05.004","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"40","author":"Long","year":"2019","journal-title":"Clin Chest Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s12325-020-01578-6","article-title":"Estimation of the prevalence of progressive Fibrosing interstitial lung diseases: systematic literature review and data from a physician survey","volume":"38","author":"Olson","year":"2021","journal-title":"Adv Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/annrheumdis-2020-217230","article-title":"Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)","volume":"80","author":"Spagnolo","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1159\/000488358","article-title":"Predictive factors for the Long-term deterioration of pulmonary function in interstitial lung disease associated with anti-aminoacyl-tRNA Synthetase antibodies","volume":"96","author":"Yamakawa","year":"2018","journal-title":"Respiration"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref23","unstructured":"Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases106579\n            ChiuYH\n            SpieringsJ\n            de JongPA\n            HoeseinFM\n            GruttersJC\n            van LaarJM\n          10.1016\/j.rmed.2021.106579Respir Med.1872021"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive Fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e023998","DOI":"10.1136\/bmjopen-2018-023998","article-title":"Systematic review and meta-analysis of prognostic factors for idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"8","author":"Kamiya","year":"2018","journal-title":"BMJ Open"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3899\/jrheum.181141","article-title":"Evolution of pulmonary function in a cohort of patients with interstitial lung disease and positive for Antisynthetase antibodies","volume":"47","author":"Gonz\u00e1lez-P\u00e9rez","year":"2020","journal-title":"J Rheumatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/jalm\/jfab108","article-title":"Myositis antibodies and interstitial lung disease","volume":"7","author":"Basuita","year":"2022","journal-title":"J Appl Lab Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"5556","DOI":"10.21037\/jtd-20-3328","article-title":"A narrative review of interstitial lung disease in anti-synthetase syndrome: a clinical approach","volume":"13","author":"Sawal","year":"2021","journal-title":"J Thorac Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1007\/s00330-019-06152-5","article-title":"Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome","volume":"29","author":"Liu","year":"2019","journal-title":"Eur Radiol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.3390\/jcm8112013","article-title":"Influence of Antisynthetase antibodies specificities on Antisynthetase syndrome clinical Spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12016-020-08822-5","article-title":"Interstitial lung disease in anti-MDA5 positive dermatomyositis","volume":"60","author":"Wu","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2169\/internalmedicine.55.5774","article-title":"Radiological and pathological correlation in anti-MDA5 antibody-positive interstitial lung disease: rapidly progressive Perilobular opacities and diffuse alveolar damage","volume":"55","author":"Chino","year":"2016","journal-title":"Intern Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/1346-8138.15128","article-title":"Anti-transcriptional intermediary factor 1-\u03b3 antibody as a biomarker in patients with dermatomyositis","volume":"47","author":"Shimizu","year":"2020","journal-title":"J Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/lqjx4h","article-title":"Interstitial lung disease in adult patients with anti-NXP2 antibody positivity: a multicentre 18-month follow-up study","author":"Yan","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1684\/ejd.2020.3750","article-title":"Anti-mi-2 antibodies characterize a distinct clinical subset of dermatomyositis with favourable prognosis","volume":"30","author":"Liang","year":"2020","journal-title":"Eur J Dermatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.autrev.2018.09.008","article-title":"Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy","volume":"18","author":"Anquetil","year":"2019","journal-title":"Autoimmun Rev"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12890-021-01802-1","article-title":"Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies","volume":"22","author":"Ge","year":"2022","journal-title":"BMC Pulm Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"778211","DOI":"10.3389\/fmed.2021.778211","article-title":"Interstitial lung disease is a major characteristic of patients who test positive for anti-PM\/Scl antibody","volume":"8","author":"Ge","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.semarthrit.2014.07.002","article-title":"Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM\/Scl antibody","volume":"44","author":"Guillen-Del Castillo","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"102355","DOI":"10.1016\/j.autrev.2019.102355","article-title":"Interstitial lung disease associated with anti-PM-Scl antibody: a single center experience","volume":"18","author":"Ussavarungsi","year":"2019","journal-title":"Autoimmun Rev"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/art.20056","article-title":"PM-Scl-75 is the main autoantigen in patients with the polymyositis\/scleroderma overlap syndrome","volume":"50","author":"Raijmakers","year":"2004","journal-title":"Arthritis Rheum"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/0961203308089442","article-title":"Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases","volume":"17","author":"Cavazzana","year":"2008","journal-title":"Lupus"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/annrheumdis-2018-214439","article-title":"Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes","volume":"78","author":"Spielmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1136\/annrheumdis-2020-217096","article-title":"Immune-mediated necrotizing myopathies and interstitial lung disease are predominant characteristics in anti-Ku positive patients with idiopathic inflammatory myopathies","volume":"81","author":"Yang","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/MD.0b013e31824d9cec","article-title":"Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease","volume":"91","author":"Rigolet","year":"2012","journal-title":"Medicine"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"105895","DOI":"10.1016\/j.rmed.2020.105895","article-title":"Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sj\u00f6gren syndrome","volume":"163","author":"Buvry","year":"2020","journal-title":"Respir Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"106134","DOI":"10.1016\/j.rmed.2020.106134","article-title":"Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis","volume":"172","author":"Xing","year":"","journal-title":"Respir Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","article-title":"Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis","volume":"78","author":"Sabbagh","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"274","DOI":"10.55563\/clinexprheumatol\/di1083","article-title":"Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies","volume":"40","author":"Cavagna","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00296-017-3718-1","article-title":"A review of the role and clinical utility of anti-Ro52\/TRIM21 in systemic autoimmunity","volume":"37","author":"Lee","year":"","journal-title":"Rheumatol Int"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12016-021-08911-z","article-title":"Anti-Ro52 autoantibody is common in systemic autoimmune rheumatic diseases and correlating with worse outcome when associated with interstitial lung disease in systemic sclerosis and autoimmune myositis","volume":"63","author":"Chan","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","article-title":"Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease","volume":"60","author":"Xu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3899\/jrheum.220139","article-title":"Coexisting of anti-Ro52 autoantibodies on anti-MDA5 autoantibodies-positive dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk","volume":"50","author":"Lv","year":"2022","journal-title":"J Rheumatol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12931-019-1231-7","article-title":"Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody","volume":"20","author":"Sclafani","year":"2019","journal-title":"Respir Res"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.55563\/clinexprheumatol\/bjb2gf","article-title":"Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single Centre cohort study","volume":"40","author":"Bozzalla-Cassione","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/rheumatology\/kev300","article-title":"Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease","volume":"55","author":"Gunnarsson","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"161","DOI":"10.22034\/iji.2022.91412.2077","article-title":"Anti-Ro52 antibody as a protective factor for pulmonary fibrosis in primary Sj\u00f6gren\u2019s syndrome","volume":"19","author":"Li","year":"2022","journal-title":"Iran J Immunol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2013-203863","article-title":"International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"73","author":"Agmon-Levin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: the international consensus on ANA patterns (ICAP) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1097\/RHU.0000000000001350","article-title":"Myositis-specific antibodies and myositis-associated antibodies in patients with idiopathic inflammatory myopathies from the PANLAR myositis study group","volume":"27","author":"Gonz\u00e1lez-Bello","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3899\/jrheum.160618","article-title":"A negative antinuclear antibody does not indicate autoantibody negativity in myositis: role of Anticytoplasmic antibody as a screening test for Antisynthetase syndrome","volume":"44","author":"Aggarwal","year":"2017","journal-title":"J Rheumatol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.autrev.2018.10.004","article-title":"Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays","volume":"18","author":"Damoiseaux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1586\/1744666X.3.5.721","article-title":"Clinical implication of autoantibodies in patients with systemic rheumatic diseases","volume":"3","author":"Satoh","year":"2007","journal-title":"Expert Rev Clin Immunol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.semarthrit.2021.03.012","article-title":"Detection of multiple myositis-specific autoantibodies in unique patients with idiopathic inflammatory myopathy: a single Centre-experience and literature review: systematic review","volume":"51","author":"Van Horebeek","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/rheumatology\/key451","article-title":"Combining immunofluorescence with immunoblot assay improves the specificity of autoantibody testing for myositis","volume":"58","author":"Infantino","year":"2019","journal-title":"Rheumatology"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"212","DOI":"10.55563\/clinexprheumatol\/3cuc1s","article-title":"Pitfalls in the detection of myositis specific antibodies by lineblot in clinically suspected idiopathic inflammatory myopathy","volume":"38","author":"Piette","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"106581","DOI":"10.1016\/j.rmed.2021.106581","article-title":"Diagnosis of myositis-associated interstitial lung disease: utility of the myositis autoantibody line immunoassay","volume":"187","author":"Jee","year":"2021","journal-title":"Respir Med"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1136\/ard.61.10.929","article-title":"Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease","volume":"61","author":"Peene","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.autrev.2011.03.004","article-title":"Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study","volume":"10","author":"Ghillani","year":"2011","journal-title":"Autoimmun Rev"},{"key":"ref71","first-page":"134","article-title":"Anti-Ro52 and\/or anti-Ro60 immune reactivity: autoantibody and disease associations","volume":"126","author":"Zampeli","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"ref72","first-page":"891","article-title":"Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis\/dermatomyositis","volume":"32","author":"Ceribelli","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"112340","DOI":"10.1016\/j.biopha.2021.112340","article-title":"TRIM proteins in fibrosis","volume":"144","author":"Qian","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.4049\/jimmunol.0804121","article-title":"Gene disruption study reveals a nonredundant role for TRIM21\/Ro52 in NF-kappaB-dependent cytokine expression in fibroblasts","volume":"182","author":"Yoshimi","year":"2009","journal-title":"J Immunol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: molecular mechanisms and potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1800564","DOI":"10.1183\/13993003.00564-2018","article-title":"Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis","volume":"52","author":"Kwapiszewska","year":"2018","journal-title":"Eur Respir J"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1068402\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T06:44:53Z","timestamp":1678949093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1068402\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":77,"alternative-id":["10.3389\/fmed.2023.1068402"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1068402","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"article-number":"1068402"}}